Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common diabetes pill protect hearts of dialysis patients?

NCT ID NCT05179668

First seen Jan 08, 2026 · Last updated May 19, 2026 · Updated 19 times

Summary

This study tested whether dapagliflozin, a drug used for diabetes, can improve heart structure and be safe in people with kidney failure who are on dialysis. 220 adults on maintenance dialysis (with or without diabetes) received either the drug or a placebo. The goal was to see if the drug could reduce heart muscle thickening, a common problem in dialysis patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dialyseinstitut Dr. Waller

    Feldbach, 8330, Austria

  • Dialyseinstitut Gießauf GmbH

    Graz, Austria

  • Hanusch Krankenhaus

    Vienna, 1140, Austria

  • Klinik Donaustadt

    Vienna, 1220, Austria

  • Klinik Favoriten

    Vienna, 1100, Austria

  • Klinik Landstraße

    Vienna, 1030, Austria

  • Krankenhaus Hietzing

    Vienna, 1130, Austria

  • Medical University of Vienna

    Vienna, 1090, Austria

  • Wiener Dialysezentrum

    Vienna, 1220, Austria

Conditions

Explore the condition pages connected to this study.